AIM ImmunoTech releases CEO update on Ampligen pancreatic cancer program progress

AIM ImmunoTech Inc. Common Stock

AIM ImmunoTech Inc. Common Stock

AIM

0.00
  • AIM ImmunoTech released a CEO update citing “growing momentum” in its pancreatic cancer program for Ampligen.
  • Phase 2 DURIPANC trial enrollment completed; all patients dosed for Ampligen combined with AstraZeneca’s Imfinzi.
  • Update cited encouraging interim clinical observations with a favorable safety profile; Phase 3 planning ongoing.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AIM ImmunoTech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607070903PRIMZONEFULLFEED9757693) on July 07, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.